Targeted cytotoxic somatostatin analogs: A modern approach to the therapy of various cancers

Drugs of the Future

Volumn 26, Issue 3, 2001, Pages 261-270

  Nagy, A ^a   Schally, A V ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLINODOXORUBICIN; AN 162; AN 163; AN 258; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

BRAIN TUMOR; BREAST CANCER; CANCER; CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; REVIEW;

EID: 0034986641     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.03.858706     Document Type: Review

References (68)

1. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
2. Hypothalamic regulatory hormones
3. Hypothalamic and other peptide hormones
4. Oncological applications of somatostatin analogues
5. Mechanisms of antineoplastic action of somatostatin analogs
6. Multiple actions of somatostatin in neoplastic disease
7. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
8. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin
9. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin
10. Molecular biology of somatostatin receptors
11. Molecular pharmacology of somatostatin receptor subtypes
12. Selective coupling of methotrexate to peptide hormone carriers through a γ-carboxamide linkage of its glutamic acid moiety: Benzotriazole-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling
13. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice
14. 1] octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation
15. 3] octreotide: The Rotterdam experience with more than 1,000 patients
16. Yttrium-90-labelled somatostatin analogue for cancer treatment
17. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
18. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
19. High-yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1,000 times more potent; Structure-activity relationship of daunosamine-modified derivatives of doxorubicin
20. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
21. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis
22. The anthracyclines: Will we ever find a better doxorubicin?
23. The molecular pharmacology of doxorubicin in vivo
24. Doxorubicin-induced cardiac toxicity
25. The anticancer agent adriamycin can be actively cytotoxic without entering cells
26. Multidrug resistance
27. Activity of 3′-(3-cyano-4-morpholinyl)-3′-deaminoadriamycin in sensitive and resistant L5178Y lymphoblasts in vitro
28. Nemorubicin
29. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative, 500-1,000 times more potent
30. Design, synthesis and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
31. The covalent binding of daunomycin and adriamycin to antibodies with retention of both drug and antibody activities
32. cis-Aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from lysosomotropic conjugate
33. (6-Maleimidocaproyl)hydrazone of doxorubicin: A new derivative for the preparation of immunoconjugates of doxorubicin
34. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: In vitro and in vivo studies
35. Polymer conjugates with anticancer activity
36. Drug delivery systems employing 1,4- or 1,6-elimination: Poly(ethylene glycol) prodrugs of amine-containing compounds
37. Drug delivery systems based on trimethyl lock lactonization: Poly(ethylene glycol) prodrugs of amino-containing compounds
38. Anti-tumor activity of daunorubicin linked to poly-L-aspartic acid
39. Carboxylic ester hydrolases
40. 3]octreotide by mouse and human pituitary tumor cells: Increase by unlabeled octreotide
41. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin, AN-238
42. Inhibition of UCI-107 human ovarian carcinoma by a targeted cytotoxic analog of somatostatin AN-238
43. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: Implications for the design of preclinical studies
44. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses
45. Somatostatin analogs: Future directions
46. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver
47. 3-octreotide (DOTATOC): A pilot study in human gliomas
48. Somatostatin receptor-based scintigraphy and antitumor treatment - An expanding vista
49. Expression of somatostatin receptors in peritumoral veins of human tumors
50. Somatostatin analogs inhibit angiogenesis in the chick chorioallantoic membrane
51. Peptide analogs in the therapy of prostate cancer
52. Somatostatin receptors in human prostate and prostate cancer
53. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers
54. 1]octreotide scintigraphy
55. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238
56. Somatostatin receptors in human renal cell carcinomas
57. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238
58. 5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: Comparison of mRNA analysis with receptor autoradiography
59. 3 in paraffin-imbedded breast cancer tissue using subtype-specific antibodies
60. Expression of somatostatin receptor subtypes in human brain tumors
61. Regression of U-87 MG human glioblastoma in nude mice after treatment with a cytotoxic somatostatin analog AN-238
62. A targeted cytotoxic somatostatin analogue AN-238 inhibits growth of H-69 small cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice
63. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
64. 2 somatostatin receptor gene expression in human pancreatic and colorectal cancer
65. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A North Central Cancer Treatment Group study
66. Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo
67. 2) gene expression and administration of cytotoxic somatostatin analog AN-238
68. Human ovarian cancers express somatostatin receptors